



Animal and Plant
Health Inspection
Service

Veterinary Services

Center for Veterinary
Biologics

1920 Dayton Avenue
PO Box 844
Ames, IA 50010

(515) 337-6100

Considerations to Requests for Changes to Outlines of Production for Bacterial Products

Document Number: CVB-WI-0180

Revision: 02

Previous Number: PEL Reviewer Manual Ch. 4.1.3

Vault: CVB-Released

Section/Area: CVB-WI-PEL-REV

Effective Date: 21 May 2021

Notes:

Considerations to Requests for Changes to Outlines of Production for Bacterial Products

Changes to the manufacturing process of bacterial products can significantly affect the antigenic structure such that the protective antigens are hidden, reduced in number or absent. This is an important issue for inactivated products because they do not have the option of replicating in the host. In contrast, modified live bacterial products are less likely to be affected because they go through one or more replications in the host resulting in expression of target antigens. Bacteria unlike viruses do not express all or most of the possible genes under most *in vitro* growth conditions. Many of the genes are inducible by various signals and remain repressed until those signals are present. For example certain outer membrane proteins in *Mannheimia haemolytica* are induced under iron limiting conditions but not under iron replete conditions (1). There are many changes in manufacturing that may affect antigen expression. This guide will list many of these but be aware there may be other considerations.

Below are listed factors that may have an effect on the final product. These have been broken into modifications that affect antigen expression, recovery and modification of the expressed antigen(s) and formulation.

EXPRESSION

This section refers to the portion of the manufacturing process that may have an effect on the expression of the antigens of interest. Changes to the host cells (for intracellular bacteria, mycoplasma, and parasites), and in the nutrients, atmosphere (3, 4), pH, *etc.* can affect a change in the presence or amount of an antigen. Sometimes expression may not change but availability changes (the antigen of interest is modified or hidden by other structures). Regardless, proposals to change these conditions must be supported by evidence the antigen(s) of interest is/are expressed at levels and in a form similar to the original, licensed manufacturing process. This is a data driven process that must include analytical information comparing the current process to the proposed process. Firms should be encouraged to summarize all historical changes (minor or major that have occurred with a particular product each time they propose a new change. Multiple minor changes can become significant over time. Examples of recent reviews of outline changes of bacterial products may be found in mail logs (ML) [REDACTED]

[REDACTED] Searching for reports under the subtype of manufacturing processes in the ML will allow you to find additional examples of reviews of proposed manufacturing changes.

Major changes to outlines of production for bacterial products are outlined below

- 1) Medium (data should be requested to support that the medium changes described below would not change the antigenic profile of the product (3)
 - a) Change in source (manufacture)-all sources are not equivalent and need to be justified.

- i) In most cases, there should be a vendor and catalogue number included with media, plates, etc. ELISA plates should not include “or equivalent,” since there are many different binding capacities (e.g. Immulon 2,3,4, etc.).
- ii) A common component for some bacterial media is BSA. The kind of BSA incorporated into the media does not usually affect most bacteria but there are some (e.g., leptospirosis, borrelia, etc.) that require fraction IV (esterified) BSA for growth. Some purification processes can vary from manufacturer to manufacturer as well, so one source of type of media can provide varying nutrients to bacteria
- b) Change in composition-changing the medium is a major change
 - i) mammal to fish or plant
 - ii) Complex to synthetic, chemically defined or vice versa
 - iii) Ratio of components
- 2) Change in buffer composition-salts, trace minerals may significantly change expression conditions
 - a) Vessel used for growth-Changes in the vessel can result in significant changes in antigen expression; regulated growth in a fermenter is different than static growth in a flask or carboy as is growth in liquid versus solid medium.
 - i) Regulated fermenter vs. flask or carboy
 - ii) Large scale vs. small
 - iii) Liquid medium vs. solid or semi-solid
 - iv) Chemostat (steady state, continuous culture) vs. batch
 - v) Thin film vs. bulk
 - b) Agitation-this effects the gas exchange and therefore the type of metabolism (aerobic versus anaerobic) and therefore antigen expression (3, 4).
 - i) Some vs. none
 - ii) Little vs. a lot (low vs high shear)
 - iii) Active sparging versus none
 - (1) O₂
 - (2) Air
 - (3) Anaerobic e.g. w/N₂
 - (4) CO₂
 - iv) Monitoring and adjusting O₂ and CO₂ vs. not
 - c) pH
 - i) regulated vs. not
 - ii) change in pH
 - d) Iron limitation vs. iron replete (limitation of other nutrients may also be a factor) (1)
 - i) Low iron medium
 - ii) Iron chelators
 - e) Temperature of incubation (2)
 - f) Stage of growth (when harvested)

- i) Log phase
- ii) Stationary phase

RECOVERY AND MODIFICATION

This stage does not affect the expression of the antigen but instead the recovery or level of harvest, the level of other stuff that may be present in the harvested fluids and end up in the formulated product, and potential modifications to the antigen. Therefore, changes at this stage of production may be considered minor in some cases. The reviewer should evaluate the effect a change these processes have on the amount of antigen(s) present, the presence or absence of extraneous material (e.g. Endotoxin), and modification of the antigen(s) (e.g. proteolysis, denaturation),

- 1) Conditions
 - a) Centrifugation vs. filtration
- 2) Washing vs. no washing
 - a) Change in Molecular weight cut-off (MWCO) of membranes
 - b) Buffer changes
- 3) Post-harvest processing
 - i) Lysis
 - (1) Mechanical
 - (a) French press
 - (b) Sonication
 - (c) Microfluidizer
 - (d) Combination
 - (2) Chemical
 - (3) Enzymatic
 - ii) Chromatography
- 4) Inactivation
 - a) Agent change. Note that change from one inactivating agent to another is a significant change.
 - b) Procedure
 - i) Temperature
 - ii) pH
 - iii) Medium
 - iv) Time
 - v) Scale

FORMULATION

- 1) Change in adjuvant procedure
 - a) Bulk or stepwise

- b) Order of addition
- 2) Change in adjuvant (this is a major change that requires the material be treated as a new product.)

How important are these changes? That depends on the organism and the composition of the product. Centrifugation vs. filtration may be very important if the important antigen is easily removed by washing and the filtration step includes vigorous washing (diafiltration) or of no importance if the antigen of interest is firmly bound to the cell. Some antigens require vigorous oxygenation for expression, others do not. In order to determine how the proposed changes should be justified, the reviewer should seek information as follows:

1. Literature search
2. Input from the laboratory supervisor for the bacteriology section of the laboratory. The current bacteriology laboratory supervisor is Angela Walker.
3. Input from bacteriology section leader
4. If the bacteriology section leader and the bacteriology laboratory supervisor will not be available for an extended amount of time, it is also acceptable to seek input directly from laboratory personnel identified to be experts for the agent you are working with. To find the USDA lab expert for different antigens, go to LSRTIS. Click on the "Admin" tab, and then select "USDA Employee Agent Search," and then do a search based on the applicable agent.

The burden of proof is on the firm to demonstrate the change has not altered the product. Various analytical tools such as PAGE, Western Blotting, HPLC, IEF, protein sequencing etc. may be of use. Simple serological tests are probably of no value unless they measure a functionally relevant parameter such as neutralization, agglutination or other related to the protective mechanism.

The change may require licensing the product as a new product. To confirm if a new product code is required, seek input from the CodeMaster. Typically, major changes that could reasonably affect both safety and efficacy of the product, and where pivotal studies would need to be repeated, would require a new Product Code.

Potency tests – For inactivated bacterial products tested by an *in vitro* test, production changes could alter the relationship between the reference bacterin and current serials of product.

References

1. Deneer, H. G. and A. A. Potter, (1989). Iron-repressible Outer-membrane Proteins of *Pasteurella haemolytica*. *Journal of General Microbiology* 135, 435-443.

2. Maurelli, A. T., B. Blackmon, and R. Curtiss III (1984). Temperature-Dependent Expression of Virulence Genes in *Shigella* Species. *Inf. and Imm.* 43(1), 195-201.
3. Isaacson, R. E. (1980). Factors Affecting Expression of the *Escherichia coli* Pilus K99. *Inf. and Imm.* 28(1), 190-194.
4. Da Silva, A. J. et al (2008). Bioreactor aeration conditions modulate growth and antigen expression during *Erysipelothrix rhusiopathiae* cultivation. *Appl. Microbiol. Biotechnol.* 79, 23-31.